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Background/Aims. Studies on 46,XY partial gonadal dysgenesis (PGD) have focused on molecular, gonadal, genital, and hormone
features; little is known about follow-up. Our aim was to analyze long-term outcomes of PGD.Methods. Retrospective longitudinal
study conducted at a reference service in Brazil. Ten patients were first evaluated in the 1990s and followed up until the 2010s; follow-
up ranged from 13.5 to 19.7 years. All were reared as males and had at least one scrotal testis; two bore NR5A1 mutations. Main
outcomes were: associated conditions, pubertal development, and growth. Results. All patients had normal motor development
but three presented cognitive impairment; five had various associated conditions. At the end of the prepubertal period, FSH was
high or high-normal in 3/6 patients; LH was normal in all. At the last evaluation, FSH was high or high-normal in 8/10; LH was
high or high-normal in 5/10; testosterone was decreased in one. Final height in nine cases ranged from −1.57 to 0.80 SDS. All
had spontaneous puberty; only one needed androgen therapy. Conclusions. There is good prognosis for growth and spontaneous
pubertal development but not for fertility. Though additional studies are required, screening for learning disabilities is advisable.
1. Introduction
Partial gonadal dysgenesis (PGD), one of the 46,XY disorders
of sex development (DSD) [1], is a rare disorder characterized
by sex ambiguity due to variable degrees of testicular dysge-
nesis in individuals without a syndromic picture who have a
normal male karyotype.
The histology of dysgenetic testes may vary from gonads
with a few tubular structures and predominance of fibrous
tissue to those with mild abnormalities, such as reduction of
mean tubular diameter and mean number of germ cells and
Sertoli cells per tubular profile [2]. Dysgenetic testes may be
found bilaterally ormay be associatedwith streak gonads, and
the degree of embryonic Sertoli and Leydig cell dysfunction
determines the degree of virilization of the internal and
external genitalia [2]. Thus, the genital phenotype may range
predominantly from male to female, including cases of
marked sex ambiguity [3–5].
PGDwas initially considered bymany authors as a variant
of 46,XY complete gonadal dysgenesis (CGD), which is
characterized by bilateral streak gonads and female internal
and external genitalia. However, mutations in SRY (sex
determining region Y) gene, which have been described in
many cases of XY CGD [6, 7], are rarely seen in PGD [8–
10]. In recent years, both heterozygous and homozygous
mutations in NR5A1 (Nuclear Receptor Subfamily 5, Group A,
Member 1) gene, which codifies the SF1 (steroidogenic factor 1)
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protein, have been found in about 15% of patients with PGD
[11–13].
There is a high risk of germ cell neoplasia in the streak
gonads of these individuals, which may reach 35% [1]; as a
consequence, prophylactic gonadectomy is indicated [1, 14].
Tumors may also arise in the dysgenetic testes, particularly
those with marked dysgenesis, which are not located in the
scrotum [1, 15]. Thus, when the patients are raised as males,
preservation of testes must be carefully evaluated.
The main differential diagnosis of PGD is mixed gonadal
dysgenesis (MGD), one of the DSD associated with sex
chromosome abnormalities [1]. PGD andMGD share similar
gonadal and genital features; however, in MGD there is
mosaicismwith a 45,X cell line and one ormore lineages with
a normal or structurally abnormal Y chromosome [16]. As a
consequence, patients with MGD may show clinical features
of Turner syndrome, including short stature, dysmorphisms,
and cardiovascular and renal malformations.
Distinguishing PGD from MGD depends on the kary-
otype, which must include the analysis of a sufficient number
of cells to rule out mosaicism with high degree of confidence
[17, 18].
Most studies on PGD focused on its gonadal and genital
and sex hormone features and also on the search for muta-
tions in genes involved in testis differentiation; however, little
is known about other aspects of its clinical picture, including
growth, puberty, and possible associated clinical conditions.
As a consequence, when diagnosis is made, it is difficult to
provide complete information to the parents on prognosis.
Between 1996 and 1998 we had the opportunity to
evaluate 13 patients with PGD, all reared as males, using the
same clinical and histopathological criteria [2].These patients
had also been subject to the same cytogenetic and molecular
evaluations [2, 10], andmany were followed in our University
Hospital since then.The aimof this studywas to analyze long-
term follow-up of these patients, in order to better establish
the prognosis of this condition.
2. Patients and Methods
Ten of 13 patients previously reported by our group (Scolfaro
et al.) [2] were followed up in the University Hospital and
were included in this study. Seven of them were regularly
followed up in the pediatric endocrinology service and
the other three were seen recently by us. These ten cases,
described in Table 1, correspond to Scolfaro et al.’s cases 1, 3–9,
11, and 13.
The patients were first seen by us in the 1990s with ages
ranging from 14 days to four years; nine were referred in the
first year of life. In Scolfaro et al.’s study, the diagnosis of PGD
was supported by the findings of ambiguous genitalia, a G-
banded 46,XY karyotype with analysis of 16–32 cells, negative
response of testosterone to hCG test without increase in
precursors of testosterone synthesis (progesterone, dehy-
droepiandrosterone, and androstenedione), low AMH levels,
presence of a streak gonad in two patients, and, in all cases,
at least one gonad with histopathological features compatible
with testicular dysgenesis (abnormal mean tubular diameter,
severe tubular hypoplasia, low tubular fertility index, severe
germinal hypoplasia, and/or hyperplasia of Sertoli cells).
At the time of the first visit to our service, assess-
ment of luteinizing hormone (LH), follicle-stimulating hor-
mone (FSH), progesterone, androstenedione, and dehy-
droepiandrosterone had been performed by radioimmunoas-
say in our service and anti-Mu¨llerian hormone (AMH) by
an enzyme-linked immunosorbent assay, using antibodies
against human recombinant AMH in the laboratory of the
Unite´ de Recherches sur l’Endocrinologie du Developpe-
ment (INSERM), Montrouge, France. The human chorionic
gonadotropin (hCG) test had been performed with measure-
ment of total testosterone levels before and 24 hours after the
last of a series of 3 daily intramuscular injections of 2000 IU
of hCG (Profasi, Serono) and was considered normal when
the patient presented an increase in testosterone level of more
than 4.9 nmol/L (1.4 ng/mL) [2].
Maternal age at birth ranged from 19 to 46 years (mean
28 years) and paternal age from 16 to 52 years (mean 31.1
years). Within nine full-term gestations, birth weight ranged
from 2470 to 3750 g (mean 3097 g) and length from 46
to 51.5 cm, with an average of 48.4 cm. No patients had
consanguineous parents and only two had a family history
of genital ambiguity: case 2 (a first cousin once removed) and
case 5 (maternal aunt and great-aunt).
The urethral meatus was most frequently penile (6/10).
Bilateral dysgenetic testes were found in 6/10 cases and
dysgenetic testis with contralateral streak was found in two.
In the remaining cases there was unilateral dysgenetic testis;
in one of the cases the contralateral gonad was absent and
in the other it had not been biopsied. Mu¨llerian derivatives
were found in two patients. All patients were raised as boys
and had at least one testis in the scrotum. All had absence of
mutations in SRY or WT1 (Wilms Tumor 1) genes [10]. Two
of them (cases 2 and 3) had heterozygous NR5A1 mutations,
a p.Lys38∗ and a p.Ser32Asn, respectively.
At the time of the last clinical evaluation in our ser-
vice, patients’ ages ranged from 15.5 to 19.8 years (mean
18 years); the mean time between first and last clinical
evaluation in our service was 17.3 years (range 13.5–19.7
years). Follow-up data were obtained from the medical files
and included neuromotor development, learning disabilities,
congenital malformations, acquired diseases, concentrations
of follicle-stimulating hormone (FSH), luteinizing hormone
(LH), and total testosterone (determined by electrochemi-
luminescence), semen analysis, and occurrence of testicular
neoplasia. The normal pubertal male range for FSH, LH, and
testosteronewas, respectively, 1.5–12.4 IU/L, 1.7–8.6 IU/L, and
2.86–8.10 ng/mL. Semen analysis was done according to the
latest World Health Organization’s guidelines [19].
Growth data were also collected frommedical records, as
well as data on pubertal development, which was evaluated
considering the age of onset of the first signs of puberty
and its progression. Patients’ heights were expressed as
standard deviation score (SDS) using reference data from
CDC (NCHS/CDC 2000). Final height was considered when
growth rate was ≤1.0 cm/year in patients who had completed
pubertal development (at least Tanner stage 4). Whenever
measurement of biological parents was available, the target
International Journal of Endocrinology 3
Ta
bl
e
1:
D
es
cr
ip
tio
n
of
th
es
am
pl
ea
nd
da
ta
fro
m
th
ei
ni
tia
le
va
lu
at
io
n
in
ou
rs
er
vi
ce
.
Ca
se
1
2
3
4
5
6
7
8
9
10
A
ge
at
la
st
cli
ni
ca
l
ev
al
ua
tio
n
(y
ea
rs
)
18
.4
18
,3
17.
7
15
.5
17.
4
19
.8
17.
5
18
.6
18
.5
17.
9
A
ge
at
fir
st
vi
sit
(m
on
th
s)
2
6
3
0.
5
7
1.5
48
6
0.
5
3
M
at
er
na
la
ge
at
bi
rt
h
29
N
A
38
19
23
46
19
27
32
19
Pa
te
rn
al
ag
ea
tb
irt
h
32
N
A
38
36
23
52
16
32
28
23
Pr
eg
na
nc
y
co
m
pl
ic
at
io
ns
H
yp
er
te
ns
iv
e
di
so
rd
er
N
A
—
—
Bl
ee
di
ng
in
th
e
1s
tt
rim
es
te
r
H
yp
er
te
ns
iv
e
di
so
rd
er
—
H
yp
er
te
ns
iv
e
di
so
rd
er
;
pr
ee
cla
m
ps
ia
—
—
Bi
rt
h
w
ei
gh
t(
g)
35
00
28
00
30
00
24
70
∗
30
00
35
50
37
50
16
50
∗
#
28
50
29
50
Bi
rt
h
le
ng
th
(c
m
)
48
48
48
47
48
51
.5
50
41
46
49
Fa
m
ily
hi
sto
ry
of
se
x
am
bi
gu
ity
—
1s
tc
ou
sin
on
ce
re
m
ov
ed
—
—
M
at
er
na
la
un
t
an
d
gr
ea
t-a
un
t
—
—
—
—
—
U
re
th
ra
lm
ea
tu
s
PE
R
PE
N
PE
R
PE
N
PE
N
PE
N
N
L
PE
N
PE
R
PE
N
Ri
gh
tg
on
ad
:t
yp
e,
lo
ca
tio
n
(a
ge
in
m
on
th
s)
D
T,
SC
(1
1)
St
re
ak
,I
N
(1
22
)
D
T,
SC
(3
6)
D
T,
SC
(1
6)
D
T,
SC
(1
6)
N
B,
SC
(1
08
)
D
T,
IN
(8
4)
D
T,
IN
(1
9)
D
T,
IN
(2
6)
D
T,
IN
(3
6)
Le
ft
go
na
d:
ty
pe
,l
oc
at
io
n
(a
ge
in
m
on
th
s)
D
T,
SC
(1
1)
D
T,
IN
(1
22
)
D
T,
SC
(3
6)
D
T,
SC
(1
6)
D
T,
SC
(1
6)
D
T,
IN
(1
08
)
Ab
se
nt
D
T,
SC
(1
9)
St
re
ak
,A
B
(2
6)
D
T,
IN
(3
6)
In
te
rn
al
ge
ni
ta
lia
N
or
m
al
m
al
e
U
G
S
va
gi
na
an
d
ut
er
us
U
G
S
bl
in
d-
en
di
ng
va
gi
na
N
or
m
al
m
al
e
N
or
m
al
m
al
e
N
or
m
al
m
al
e
N
or
m
al
m
al
e
N
or
m
al
U
G
S
ru
di
m
en
ta
ry
ut
er
us
N
or
m
al
m
al
e
To
ta
lt
es
to
ste
ro
ne
(n
m
ol
/L
)
aft
er
hC
G
sti
m
ul
at
io
n
te
st
(a
ge
in
m
on
th
s)
1.4
(7
)
<
0.
3
(4
4)
<
0.
3
(3
0)
1.7
(b
as
al
te
sto
ste
ro
ne
)
(0
.5
)
<
0.
3
(1
0)
1.0
(9
2)
<
0.
3
(7
8)
<
0.
3
(1
3)
<
0.
3
(2
0)
<
0.
3
(3
1)
A
M
H
(p
m
ol
/L
)(
ag
ei
n
m
on
th
s)
§
118
(7
)
71
(4
4)
52
(3
0)
98
(0
.5
)
114
(1
0)
11
3
(9
2)
73
(7
8)
10
7
(1
3)
11
(2
0)
25
(3
1)
A
B:
ab
do
m
in
al
;D
T:
dy
sg
en
et
ic
te
sti
s;
IN
:i
ng
ui
na
l;
N
A
:n
ot
av
ai
la
bl
e;
N
B:
no
tb
io
ps
ie
d
(n
or
m
al
at
pa
lp
at
io
n)
;N
L:
no
rm
al
;P
EN
:p
en
ile
;P
ER
:p
er
in
ea
l;
SC
:s
cr
ot
al
;U
G
S:
ur
og
en
ita
ls
in
us
;A
M
H
:a
nt
i-M
u¨l
le
ria
n
ho
rm
on
e;
m
o:
m
on
th
s.
∗
Sm
al
lf
or
ge
sta
tio
na
la
ge
;#
pr
et
er
m
ge
st
at
io
n.
§ N
or
m
al
ra
ng
e:
0.
5–
12
m
o
=
25
1–
67
9p
m
ol
/L
;1
2.
01
–4
8m
o
=
36
0–
63
8p
m
ol
/L
;4
8.
01
–8
4m
o
=
30
9–
56
6p
m
ol
/L
;8
4.
01
–1
08
m
o
=
23
4–
43
8p
m
ol
/L
.
4 International Journal of Endocrinology
Age (years)
20.0017.5015.0012.5010.007.50
FS
H
 (I
U
/L
)
1000.00
100.00
0.00
10.00
1.00
10
9
8
7
6
5
4
3
2
1
Figure 1: FSH levels measured by electrochemiluminescence at
different ages in patients with partial gonadal dysgenesis. FSH values
are presented on the 𝑦-axis on a logarithmic scale. Dotted lines on
the𝑦-axis represent the upper and lower normal limits for FSH levels
in pubertal boys (1.5–12.4 IU/L).
height was calculated as (maternal height + paternal height +
12.5 cm)/2 ± 6,5 cm [20].
The Institutional Review Board approved this study
(776/2007).
3. Results
All patients had normal motor development but three pre-
sented learning disabilities of unknown etiology (which
were mild in two cases and moderate in one). Five had
various associated conditions, including vesicoureteral reflux
in two cases and facial dysmorphisms in one patient. Primary
hypothyroidism with negative antithyroid antibodies was
diagnosed in one of the patients with a NR5A1 mutation
when he was 12 years old (case 2); hearing loss due to middle
ear infections, psychiatric problems, and obesity were also
observed (one case each) (Table 2). There was no case of
testicular neoplasia.
Results of measurements of gonadotropins (FSH and LH)
and testosterone during follow-up were also analyzed. Data
on the measurement of gonadotropins at the end of the
prepubertal period, between ten and 12 years, were available
for six patients (cases 2, 4, 6, 7, 8, and 10). FSH levels were in
the upper limit of the normal male pubertal range or higher
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Figure 2: LH levels measured by electrochemiluminescence at
different ages in patients with partial gonadal dysgenesis. FSH values
are presented on the 𝑦-axis on a logarithmic scale. Dotted lines on
the 𝑦-axis represent the upper and lower normal limits for LH levels
in pubertal boys (1.7–8.6 IU/L).
in 3/6 patients (cases 2, 6, and 7), while LH levels were normal
in all cases (Figures 1 and 2).
At the last hormone evaluation (mean 16.5 years; range
12.6–20.5 years) FSH concentrations were high in 4/10
patients (cases 2, 3, 7, and 9), in the upper limit in four (4,
5, 6, and 10), and normal in two (1 and 8) (Figure 1). In turn,
LH concentrations were high in 4/10 patients (cases 3, 6, 7,
and 9), in the upper limit in one (case 1), and normal in five
(2, 4, 5, 8, and 10) (Figure 2).
Measures of testosterone could be obtained from 9/10
patients in the pubertal age range. The levels remained
normal in seven cases, remained at the low limit of normality
in one, and decreased in one patient (case 10), who received
androgen replacement therapy (Figure 3). Nine patients had
reached final height, which ranged from −1.57 to 0.80 SDS,
and in two of the eight cases for whom information on
parental height was available it was lower than their genet-
ically predicted range (target height ±6.5 cm). One patient
(case 4) was still growing, with normal velocity and within
the parental target range (Table 3).
Pubarche occurred at a mean age of 12.0 years (range
9–15 years). Eight patients had complete and spontaneous
pubertal development (≥ Tanner stage 4), one was at stage
G4P4 at 15.5 years (case 4), and another (case 10) received
androgen therapy at 17.6 years, when pubertal development
was G3P3; a few months later he reached stage G4P4.
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Figure 3: Testosterone levels measured by electrochemilumines-
cence at different ages in patients with partial gonadal dysgenesis.
FSH values are presented on the 𝑦-axis on a linear scale. Dotted
lines on the 𝑦-axis represent the upper and lower normal limits for
testosterone levels in pubertal boys (2.86–8.10 ng/mL).
The seven patients who were regularly followed up in our
pediatric endocrinology service had normal progression of
puberty; most had low testicular volume.Three patients had a
spermcount; all had severe oligozoospermia and lowmotility,
and two had also abnormal semen viscosity.
4. Discussion
In DSD, sex assignment should be based on a precise
diagnosis of the condition’s underlying etiology. Together
with genital appearance and surgical options, this will allow
the establishment of a prognosis on the need for lifelong
replacement therapy, potential fertility, and malignancy risk
[1] and also possible associated conditions. In the case of
PGD, however, prognosis is not yet clearly established.
Our results showed that all patients had normal neu-
romotor development, that most had normal growth, and
that there was no consistent pattern of associated conditions.
However, though learning disabilities are usually not a feature
of DSD, in this sample it was observed in a significant
proportion of cases (almost one-third), including a patient
with moderate difficulties. Although this association may
be casual, one may also consider the possibility that both
conditions, testicular dysgenesis and cognitive impairment,
have the same origin.
Interesting findings regarding our two patients bearing
a NR5A1 mutation are hypothyroidism in one of them
and schizophrenia in the other. Acquired primary hypothy-
roidism has not been described as a feature of patients with
PGD, with or without NR5A1mutations. The low prevalence
of these conditions in young people aged 11–18 years (0.113%)
and the fact that it is even rarer in males, with a 1 : 2.8 male to
female ratio [21], make this finding noteworthy, even though
expression ofNR5A1mRNA in thyroid gland is very low [22].
On the other hand, there is a recent publication of twowomen
with mutations in this gene who had psychiatric symptoms
[23].
The absence of testicular tumors in this sample demon-
strates that maintenance of testes in the labioscrotal folds of
patients reared as males is a relatively safe procedure, at least
until the end of puberty.
Relevant findings were obtained regarding pubertal
development. Though positive results from hCG stimulation
tests in infancy or childhood were obtained in 4/9 patients,
spontaneous pubertal development occurred in all cases.
Pubertal delay was not observed, and in 9/10 cases there was
normal progression of puberty, which strongly indicates that
there is a good prognosis regarding spontaneous puberty in
PGD patients reared as males when at least one testis may be
kept in the scrotum.
In fact, in 7/9 cases testosterone levels were in the
normal range during adolescence, though a progressive rise
of LH in half of the cases raises the possibility that Leydig
cell dysfunction may become evident in adulthood. On the
other hand, high levels of FSH in most patients, sometimes
observed early in adolescence, indicated that reproductive
function was impaired, which could be shown in those
patients whose sperm count was obtained.
Some patients with NR5A1 mutations and 46,XY PGD
have been shown to have normal testosterone production
in adolescence inducing spontaneous virilization [24–26],
though follow-up indicated a progressive gonadal failure with
elevated FSH in such cases. A similar picture was observed in
our two patients with NR5A1 mutations (cases 2 and 3) and
also in the other eight cases without mutations in this gene.
However, to the best of our knowledge, no other studies on
long-term follow-up of patients with PGD reared asmales are
available to allow comparison with our sample.
5. Conclusions
Patients with PGD raised as males who have at least one
testis in the labioscrotal region have a good prognosis for
growth and spontaneous pubertal development but not for
spontaneous fertility. Though additional studies are still
required, our results also indicated that management of
individuals with this condition should include screening for
learning disabilities.
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